Navigation

Everolimus for the second-line treatment of advanced renal cell carcinoma

Everolimus for the treatment of advanced and/or metastatic renal cell carcinoma

Status: History
Expected date of issue: August 2010
Referral date: November 2008
Process: STA
Notes:

Cancer reform strategy batch 1

Topic area:
  • Cancer
  • Urogenital
 

NICE project team

Executive Lead: Peter Littlejohns
Technical Lead: Helen Tucker
Communications manager: Alice Law
Project manager: Lori Farrar
Assessment Group / Evidence Review Group: Peninsula Technology Assessment Group (PenTAG)
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 30 September 2009
1st appraisal committee meeting: 13 January 2010
Top


 

Consultees and commentators

Consultees Commentators (no right to submit or appeal)

Manufacturers/sponsors

  • Novartis (everolimus)

Patient/carer groups

  • James Whale Fund for Kidney Cancer
  • Kidney Cancer UK
  • Macmillan Cancer Support
  • Rarer Cancers Forum

Professional groups

  • Royal College of Nursing
  • Royal College of Physicians, Medical Oncology Joint Special Committee
  • United Kingdom Oncology Nursing Society

Others

  • Department of Health
  • Welsh Assembly Government

General

  • Department of Health, Social Services and Public Safety for Northern Ireland
  • NHS Quality Improvement Scotland

Comparator manufacturer(s)

  • None

Relevant research groups

  • None

Evidence review group

  • National Institute for Health Research Health Technology Assessment Programme Peninsula Technology Assessment Group, University of Exeter (PenTAG)

Associated guideline groups

  • None

Associated ublic health groups

  • None

Top


 

Project history

Date Update
30 July 2010 This appraisal topic will be discussed at the 11 August 2010 appraisal committee meeting. During the appeal period for this appraisal, the manufacturer of everolimus (Novartis) submitted an amended dataset, which requires Committee consideration.
23 July 2010 Consultation on the final appraisal determination for this appraisal topic has been suspended. This will allow for the Appraisal Committee to consider new evidence submitted by Novartis on the total costs of use of everolimus in the NHS for the treatment of advanced renal cell cancer.  The timelines for this appraisal will be updated, when finalised. 
20 August 2010 On 11 August 2010, the NICE Appraisal Committee met to consider new evidence submitted by Novartis on the total costs of use of everolimus in the NHS for the treatment of advanced renal cell cancer.  The Committee considered the relevance of the new information and agreed that it was important to consider it fully.  In order to do that, the Committee has asked the manufacturer to submit additional modelling data to clarify the uncertainty associated with the new evidence.The Committee will therefore continue consideration of this topic at  the earliest possible meeting time.  Exact timings are to be confirmed. 
Top


 

Key documents

This page was last updated: 09 May 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.